N
Nanjing Baikang Biotechnology
Innovative antibody solutions for diagnostics and therapeutic applications, enhancing precision in healthcare
About Nanjing Baikang Biotechnology
Bioantibody is a biotechnology company specializing in the development and production of high-quality antibodies for diagnostic and therapeutic use. Operating in the healthcare and life sciences market, Bioantibody serves a diverse range of clients including research institutions, pharmaceutical companies, and clinical laboratories. The company’s business model revolves around the creation and sale of custom antibodies, which are critical for various applications such as disease diagnosis, vaccine development, and therapeutic treatments. Revenue is generated through the direct sale of these antibodies and related services, including custom antibody production and consultation. Bioantibody leverages advanced technologies and rigorous quality control to ensure the efficacy and reliability of its products, positioning itself as a key player in the biotechnology sector.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jan 2023 | $14M | $55M | Xingong Industrial Investment · Bangsheng Capital · Fang Fund Partners · Guoqian Venture Capital | ↗ |
| SPINOUT✓Other financing | Jan 2019 | $0 | — | Nanjing University | — |
Growth signals
Latest recorded traffic for Nanjing Baikang Biotechnology is 90 monthly website visits, up 200% over the last three months. Nanjing Baikang Biotechnology's team grew 27.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Nanjing Baikang Biotechnology in its local ecosystem
The Nanjing Baikang Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
Fang Fund Partners- XIXingong Industrial Investment
Bangsheng Capital
Guoqian Venture Capital
Other known investors1 additional known investor
Nanjing University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Nanjing Baikang Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Nanjing Baikang Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










